Abstract:
The invention relates to compounds of formula (I) as well as to the tautomeric forms thereof, possible enantiomeric and diastereomeric forms and the prodrugs thereof, the production and use thereof, whereby the values have the meaning as given in the description.
Abstract:
The invention relates to compounds of formula (I) as well as to the tautomeric forms thereof, possible enantiomeric and diastereomeric forms and the prodrugs thereof, the production and use thereof, whereby the values have the meaning as given in the description.
Abstract:
The invention relates to the use of PARP inhibitors in cosmetic preparations, especially in after-sun lotions. The invention further relates to cosmetic preparations that contain a PARP inhibitor and a UV absorber.
Abstract:
The invention relates to the use of phthalazine derivatives as inhibitors of the enzyme poly(ADP-ribose)polymerase or PARP (EC 2.4.2.30), and to their use as inhibitors of PARP-homologous enzymes. These phthalazine derivatives also exhibit, in particular, a selective inhibition of the PARP-homologous enzymes. The inventive phthalazine derivatives are used for producing medicaments used in the treatment of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, stroke, cerebral trauma, epilepsy, damages to the kidney, cardiovascular diseases, tumors, rheumatic diseases, diabetes mellitus, etc.
Abstract:
The invention relates to compounds of formula (I), wherein; either A or A represents CONH2, and the other radical A or A represents hydrogen, chlorine, fluorine, bromine, iodine C1-C6 alkyl, OH, nitro, CF3, CN, NR R , NH-CO-R , O-C1-C4 alkyl; X can represent N and C-R ; X , independent of X , can represent N and C-R ; R can represent hydrogen, C1-C6 alkyl, C1-C4 alkyl-phenyl, phenyl; B can represent an unsaturated, saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring having a maximum of 15 carbon atoms, an unsaturated, saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring having a maximum of 14 carbon atoms and 0 to 5 nitrogen atoms, 0 to 2 oxygen atoms or 0 to 2 sulfur atoms, which can each still be substituted with an R and a maximum of 3 of the same or different radicals R , and; R , R , R , R -R have the meanings as cited in Claim No. 1. The invention also relates to the tautomeric forms, and possible enantiomeric and diastereomeric forms of said compounds, to the prodrugs thereof and to their use as PARP inhibitors.
Abstract:
The invention relates to poly(ADP-ribose)polymerase (PARP) homologues which are characterised by an amino acid sequence with a) a functional NAD -binding site and b) no zinc-finger-sequence motif of general formula CX2CXmHX2C, wherein m is an integral number 28 or 30 and the radicals X represent any amino acid, independently of each other; and to the functional equivalents of said poly(ADP-ribose)polymerase (PARP) homologues. The invention also relates to nucleic acids coding the poly(ADP-ribose)polymerase (PARP) homologues, to antibodies with specificity for the novel protein, to pharmaceutical and gene therapy agents containing the inventive products, to methods for analytically determining the inventive proteins and nucleic acids, to methods for identifying the effectors or bonding partners of the inventive proteins, to novel PARP effectors and to methods for determining the effectiveness of effectors of this type.
Abstract:
The invention relates to cysteine protease inhibitors of the general formula (I), in which A is -(CH2)p-R , where R can be pyrrolidine, morpholine, piperidine, -NR R and formula (a) and p can be 1 or 2; B can be possibly substituted phenyl, pyridyl, pyrimidyl and pyridazyl; D is a bond, -(CH2)m-, -CH=CH-, -CC-; R is chlorine, bromine, fluorine, alkyl, NHCO alkyl, NHSO2 alkyl, NO2, -O-alkyl and NH2; R is an alkyl which can carry a possibly substituted phenyl ring, indolyl ring and cyclohexyl ring; and Y is phenyl, pyridine, pyrimidine and pyrazine; R is hydrogen, COOR and CO-Z, where Z is NR R and and formulae (b), (c), (d); n is 0, 1 or 2 and m is 0, 1, 2, 3 or 4.
Abstract:
Compounds of the formula Ia or IB where A is a saturated or monounsaturated heterocyclic, 4 - to 8-membered ring which contains one or two nitrogen atoms, and their tautomeric forms, possible enantiomeric and diastereomeric forms, their prodrugs and possible physiologically tolerated salts are useful as inhibitors of the enzyme poly(ADP-ribose)polymerase.
Abstract:
Use of phthalazine derivatives as inhibitors of the enzyme poly(ADP-ribose)polymerase or PARP and their use as inhibitors of PARP-homologous enzymes. These phthalazine derivatives also exhibit in particular a selective inhibition of the PARP-homologous enzymes.
Abstract:
The invention relates to cysteine protease inhibitors of the general formula (I), in which A is -(CH2)p-R1, where R1 can be pyrrolidine, morpholine, piperidine, -NR5R6 and formula (a) and p can be 1 or 2; B can be possibly substituted phenyl, pyridyl, pyrimidyl and pyridazyl; D is a bond, -(CH2)m-, -CH=CH-, -C.ident.C-; R2 is chlorine, bromine, fluorine, alkyl, NHCO alkyl, NHSO2 alkyl, N02, -O-alkyl and NH2; R3 is an alkyl which can carry a possibly substituted phenyl ring, indolyl ring and cyclohexyl ring; and Y is phenyl, pyridine, pyrimidine and pyrazine; R4 is hydrogen, COOR9 and CO-Z, where Z is NR10R11 and and formula (b); n is 0, 1 or 2 and m is 0, 1, 2, 3 or 4.